Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab prior to CABG in multivessel coronary artery disease
KCT0005577Phase 3Terminated
- Sponsor
- Seoul St. Mary's Hospital
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of evolocumab in coronary arteriosclerosis, sponsored by Seoul St. Mary's Hospital. Started Jan 2021; status: terminated.
02
Drugs
evolocumab
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on KCT0005577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005577.